Vertex announces casgevy® reimbursement agreement for the treatment of transfusion-dependent beta thalassemia and sickle cell disease in italy

London--(business wire)--vertex pharmaceuticals (nasdaq: vrtx) announced today a reimbursement agreement with the italian medicines agency (aifa) for eligible transfusion-dependent beta thalassemia (tdt) and severe sickle cell disease (scd) patients to access the crispr/cas9 gene-edited therapy, casgevy® (exagamglogene autotemcel). “today is a turning point for eligible people in italy living with transfusion-dependent beta thalassemia and sickle cell disease, two life-shortening diseases with.
VRTX Ratings Summary
VRTX Quant Ranking